Tyr1284
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr1284  -  HER4 (mouse)

Site Information
IVAENPEyLSEFSLK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457470

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bladder cancer ( 1 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 2 ) , bladder ( 1 )

Upstream Regulation
Treatments:
cetuximab ( 1 ) , light ( 1 )

References 

1

Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 8, 94
19878607   Curated Info

2

Moritz A (2003) CST Curation Set: 208; Year: 2003; Biosample/Treatment: cell line, 3T3/NRG1; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info